

# Peer-reviewer literature on cervical cancer elimination that we should all know

A product of the IGCS ACCESS Series



**IGCS ACCESS**

Accelerating Cervical Cancer  
Elimination Strategies Symposia

- Cervical cancer is preventable and curable, as long as it is detected early and managed effectively. Yet few diseases reflect global inequities as much as cancer of the cervix. Every two minutes a woman dies and 9 or 10 deaths occur in low- and middle-income countries.
- An ambitious, concerted and inclusive strategy has been developed to guide the elimination of cervical cancer as a public health problem, the following papers share the evidence-base for achieving the targets set for 2030 and leveraging the enablers for incremental scale up and sustaining of national programs with an equity lens.
- In 2025 IGCS launched a bold 5-year plan to bring momentum to the development and implementation of national cervical cancer strategies. This document is one early output of this work, which we commit to updating annually.
- We welcome proposals for new additions.

# IGCS



INTERNATIONAL  
GYNECOLOGIC  
CANCER SOCIETY

TOGETHER, WE CAN  
**ELIMINATE**  
CERVICAL  
CANCER

**By 2030, every high-burden country will have a national cervical cancer elimination strategy actively being implemented.**



**IGCS ACCESS**

Accelerating Cervical Cancer  
Elimination Strategies Symposia

Global strategy to accelerate the elimination of cervical cancer as a public health problem



# The IGCS ACCESS Series is in alignment with The Global Strategy of WHO

Three pillars provide a comprehensive strategy for cervical cancer control to ensure that lifetime benefits are maintained, using life-course approach

**THRESHOLD:** All countries to reach < 4 cases per 100 000 women

## 2030 Control Targets

**90%**

of girls fully vaccinated with HPV vaccine by age 15 years.

**70%**

of women are screened with a high-performance test by 35 years of age and again by 45 years of age.

**90%**

of women identified with cervical disease receive treatment (90% of women with precancer treated, and 90% of women with invasive cancer managed).



## Must-Read Papers: Cross-pillar

	Topic	Title	Reference
Cross-pillar	<b>Achieving Cervical Cancer Elimination: the impact of the 3 pillars</b>	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study	<a href="#">Simms KT, et al. The lancet oncology 2019; 20(3): 394-407.</a>
		Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries	<a href="#">Brisson M et.al. Lancet. 2020 PMID: 32007141.</a>
		Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries	<a href="#">Canfell K et.al. Lancet. 2020 PMID: 32007142.</a>
		Elimination of cervical cancer: the impact of HPV vaccination, primary HPV screening , and expanded access to cancer treatment services	<a href="#">Hall M, et.al. Molecular Aspects of Medicine</a>
	<b>Achieving Cervical Cancer Elimination: the impact of key economic, political, sociocultural, and health-system determinants</b>	Achieving cervical cancer elimination: an ecological assessment of global determinants using a policy determinant model.	<a href="#">Hyatt A et.al. The Lancet Global health 2025; 13(11): e1828-e36.</a>

## Must-Read Papers: Pillar 1 (HPV vaccination)

Topics	Title	Reference
<b>Efficacy of HPV vaccination</b>	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis	<a href="#">Drolet M, et.al. Lancet 2019; 394(10197): 497-509.</a>
	HPV Vaccination and the Risk of Invasive Cervical Cancer	<a href="#">Lei J, et.al. N Engl J Med. 2020. PMID: 32997908.</a>
<b>HPV vaccine: 1-dose schedule</b>	Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results	<a href="#">KEN SHE trial (Kenya): Barnabas RV, et al. Nat Med 2023; 29(12): 3224-32.</a>
	HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial	<a href="#">Costa Rica Vaccine Trial (CVT): Porras C, et.al. J Natl Cancer Inst Monogr. 2024; PMID: 39529529.</a>
	A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination	<a href="#">IARC India Trial: Malvi SG, et.al. J Natl Cancer Inst Monogr. 2024. PMID: 39529521.</a>
	Evidence for an HPV one-dose schedule	<a href="#">Stanley M, Schuind A, Muralidharan KK, et al. Evidence for an HPV one-dose schedule. Vaccine 2024; 42 Suppl 2: S16-s21.</a>
	Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial.	<a href="#">DoRIS (Tanzania) Trial: Watson-Jones D, et.al. Lancet Glob Health. 2025; PMID: 39890232.</a>
<b>New vaccine - prequalified for single dose</b>	Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort	<a href="#">Zhao F, et al. Lancet Reg Health West Pac 2025; 61: 101668.</a>

# Must-Read Papers: Pillar 2 (Cervical Screening with a High-Performance Test)

	Topics	Title	Reference
Pillar 2	Cervical cancer screening from the IARC perspective	The IARC Perspective on Cervical Cancer Screening	<a href="#">Bouvard V, et.al. N Engl J Med. 2021; PMID: 34758259.</a>
	Impact of HPV screening on cervical cancer risk	Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden	<a href="#">Wang J, et.al. Lancet Public Health. 2024. PMID: 39486904.</a>
	Effectiveness and cost-effectiveness of screening – Evidence from modelled evaluation	Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population.	<a href="#">Simms KT, et.al. Nat Med. 2023 PMID: 38087115.</a>
		Benefits and harms of cervical screening, triage and treatment strategies in women living with HIV	<a href="#">Hall MT, et.al. Nat Med. 2023 PMID: 38087116.</a>
	Effectiveness of HPV screening – Evidence from population-based studies	HPV screening for cervical cancer in rural India	<a href="#">Sankaranarayanan R, et.al. N Engl J Med. 2009; PMID: 19339719.</a>
		Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial	<a href="#">Denny L, et.al. J Natl Cancer Inst. 2010; PMID: 20884893.</a>
		Point-of-care HPV DNA testing of self-collected specimens and same-day thermal ablation for the early detection and treatment of cervical pre-cancer in women in Papua New Guinea: a prospective, single-arm intervention trial (HPV-STAT)	<a href="#">Vallely AJB, et.al. Lancet Glob Health. 2022; PMID: 35878625.</a>
		Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study	<a href="#">Ramírez AT, et.al; ESTAMPA Study Group. Lancet Reg Health Am. 2023 PMID: 37766799.</a>
	Accuracy of HPV self-collection	Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses	<a href="#">Arbyn M, et.al. BMJ. 2018. PMID: 30518635.</a>
	Inventory of HPV tests, including clinically validated	2023 global inventory of commercial molecular tests for human papillomaviruses (HPV)	<a href="#">Poljak M, et.al. J Clin Virol. 2024. PMID: 38518504.</a>

## Must-read Papers: Pillar 3 (Treatment and Palliative Care)

	Topics	Title	Reference
Pillar 3	Review paper	Cervical cancer	<a href="#">Tewari KS. N Engl J Med. 2025</a>
	Cervical cancer treatment in women living with HIV	Cervical cancer treatment outcomes and survival in Botswana by human immunodeficiency virus status: Ipabalele study results	<a href="#">Grover S, et.al. JNCI Cancer Spectr. 2025. PMID: 40342166.</a>
	Surgery and Radiotherapy	Benchmarking of the Cervical Cancer Care Cascade and Survival Outcomes After Radiation Treatment in a Low- and Middle-Income Country Setting	<a href="#">Grover S, et.al. JCO Glob Oncol. 2023. PMID: 37738538.</a>
		Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer	<a href="#">Plante M, et.al. N Engl J Med. 2024; PMID: 38416430.</a>
	Palliative Care	Cervical Cancer-Associated Suffering: Estimating the Palliative Care Needs of a Highly Vulnerable Population	<a href="#">Krakauer EL, et.al. JCO Glob Oncol. 2021. PMID: 34115522.</a>
		Essential Package of Palliative Care for Women With Cervical Cancer: Responding to the Suffering of a Highly Vulnerable Population	<a href="#">Krakauer EL, et.al. JCO Glob Oncol. 2021. PMID: 34115527.</a>
		Augmented Package of Palliative Care for Women With Cervical Cancer: Responding to Refractory Suffering	<a href="#">Krakauer EL, et.al. JCO Glob Oncol. 2021. PMID: 34115537.</a>